Skip to main content

Table 6 Antimicrobial susceptibility of bacteria isolated from ocular infections

From: Ocular bacterial infections at Quiha Ophthalmic Hospital, Northern Ethiopia: an evaluation according to the risk factors and the antimicrobial susceptibility of bacterial isolates

Bacterial isolate (N)

S/R

N (%)

Antibiotics tested

CN

AK

C

CIP

TC

DOX

SXT

CRO

DA

E

CH

MET

S. aureus (40)

R

S

5 (12.5)

35 (87.5)

1 (2.5)

39 (97.5)

11 (27.5)

29 (72.5)

5 (12.5)

35 (87.5)

18 (45)

22 (55)

11 (27.5)

29 (72.5)

17 (42.5)

23 (57.5)

NT

9 (22.5)

31 (77.5)

8 (20)

32 (80)

NT

7 (17.5)

33 (82.5)

CoNSa (31)

R

S

2 (6.5)

29 (93.5)

1 (3.2)

30 (96.8)

9 (29)

22 (71)

3 (9.7)

28 (90.3)

18 (58.1)

13 (41.9)

7 (22.6)

24 (77.4)

21 (67.7)

10 (32.3)

NT

12 (38.7)

19 (61.3)

9 (29)

22 (71)

NT

14 (45.2)

17 (54.8)

S. pyogenes (5)

R

S

NT

NT

2 (40)

3 (60)

NT

1 (20)

4 (80)

NT

NT

NT

0

5 (100)

0

5 (100)

0

5 (100)

NT

S. pneumoniae (8)

R

S

NT

NT

2 (25)

6 (75)

NT

4 (50)

4 (50)

2 (25)

6 (75)

3 (37.5)

5 (62.5)

NT

1 (12.5)

7 (87.5)

1 (12.5)

7 (87.5)

0

8 (100)

NT

Viridans streptococci (7)

R

S

NT

NT

3 (42.9)

4 (57.1)

NT

2 (28.6)

5 (71.4)

NT

NT

0

7 (100)

NT

1 (14.3)

6 (85.7)

0

7 (100)

NT

Enterococcus spp. (8)

R

S

NT

NT

4 (50)

4 (50)

1 (12.5)

7 (87.5)

4 (50)

4 (50)

2 (25)

6 (75)

NT

NT

NT

1 (12.5)

7 (87.5)

NT

NT

N. gonorrhoeae (1)

R

S

NT

NT

NT

0

1 (100)

0

1 (100)

NT

NT

0

1 (100)

NT

NT

NT

NT

H. influenzae (2)

R

S

NT

NT

0

2 (100)

0

2 (100)

0

2 (100)

NT

1 (50)

1 (50)

NT

NT

NT

0

2 (100)

NT

P. aeruginosa (21)

R

S

1 (4.8)

20 (95.2)

1 (4.8)

20 (95.2)

NT

4 (19)

17 (81)

NT

NT

NT

NT

NT

NT

NT

NT

K. pneumoniae (7)

R

S

2 (28.6)

5 (71.4)

1 (14.3)

6 (85.7)

3 (42.9)

4 (57.1)

1 (14.3)

6 (85.7)

5 (71.4)

2 (28.6)

2 (28.6)

5 (71.4)

4 (57.1)

3 (42.9)

3 (42.9)

4 (57.1)

NT

NT

NT

NT

Other Klebsiella spp. (5)

R

S

0

5 (100)

1 (20)

4 (80)

2 (40)

3 (60)

1 (20)

4 (80)

2 (40)

3 (60)

1 (20)

4 (80)

4 (80)

1 (20)

0

5 (100)

NT

NT

NT

NT

E. coli (15)

R

S

3 (20)

12 (80)

2 (13.3)

13 (86.7)

4 (26.7)

11 (73.3)

1 (6.7)

14 (93.3)

8 (53.3)

7 (46.7)

3 (20)

12 (80)

8 (53.3)

7 (46.7)

3 (20)

12 (80)

NT

NT

NT

NT

Enterobacter spp. (10)

R

S

1 (10)

9 (90)

1 (10)

9 (90)

1 (10)

9 (90)

0

10 (100)

6 (60)

4 (40)

5 (50)

5 (50)

4 (40)

6 (60)

2 (20)

8 (80)

NT

NT

NT

NT

Citrobacter freundii (4)

R

S

0

4 (100)

0

4 (100)

2 (50)

2 (50)

1 (25)

3 (75)

3 (75)

1 (25)

2 (50)

2 (50)

1 (25)

3 (75)

0

4 (100)

NT

NT

NT

NT

Acinetobacter spp. (5)

R

S

1 (20)

4 (80)

1 (20)

4 (80)

NT

0

5 (100)

3 (60)

2 (40)

3 (60)

2 (40)

4 (80)

1 (20)

0

5 (100)

NT

NT

NT

NT

S. marcescens (5)

R

S

1 (20)

4 (80)

1 (20)

4 (80)

2 (40)

3 (60)

0

5 (100)

1 (20)

4 (80)

1 (20)

4 (80)

2 (40)

3 (60)

1 (20)

4 (80)

NT

NT

NT

NT

Proteus spp. (3)

R

S

0

3 (100)

0

3 (100)

0

3 (100)

0

3 (100)

NT

NT

1 (33.3)

2 (66.7)

0

3 (100)

NT

NT

NT

NT

P. shigelloides (1)

R

S

0

1 (100)

0

1 (100)

0

1 (100)

0

1 (100)

0

1 (100)

0

1 (100)

0

1 (100)

0

1 (100)

NT

NT

NT

NT

Total, N (%)

R

S

16 (10.9)

131 (89.1)

10 (6.8)

137 (93.2)

45 (29.8)

106 (70.2)

17 (10.8)

141 (89.2)

75 (48.7)

79 (51.3)

39 (28.1)

100 (71.9)

70 (51.3)

66 (48.7)

9 (14.3)

54 (85.7)

22 (26.2)

62 (73.8)

20 (20.2)

79 (79.8)

0

22 (100)

21 (29.6)

50 (70.4)

  1. Notes: S Susceptible, R Resistant, CN Gentamicin, AK Amikacin, C Chloramphenicol, CIP Ciprofloxacin, TC Tetracycline, DOX Doxycycline, SXT Trimethoprim-sulfamethoxazole, CRO Ceftriaxone, DA Clindamycin, E Erythromycin, CH Clarithromycin, MET Methicillin, NT Not tested; a CoNS Coagulase negative staphylococci